Comparative Pharmacology
Head-to-head clinical analysis: GENOPTIC versus NEOMYCIN SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENOPTIC versus NEOMYCIN SULFATE.
GENOPTIC vs NEOMYCIN SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Genoptic (gentamicin ophthalmic) is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and production of nonfunctional proteins.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting protein synthesis and causing bacterial cell death by disrupting the cytoplasmic membrane.
Instill 1-2 drops into affected eye(s) every 4-6 hours; for severe infections, every 1-2 hours initially, then reduce frequency as improvement occurs.
1-2 g orally 4 times daily (8-16 g/day) for hepatic encephalopathy or intraluminal infection; 0.5-1 g orally 4 times daily for preoperative bowel preparation.
None Documented
None Documented
2-3 hours (prolonged in renal impairment to 18-24 hours); in neonates, 3-8 hours.
2-3 hours (normal renal function); prolonged to 20-60 hours in anuria
Primarily renal (70-90% unchanged) via glomerular filtration and tubular secretion; biliary/fecal <5%.
Renal (glomerular filtration) >90% unchanged; small amount biliary/fecal (<3%)
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic